 |
Lily Chen Boehringer Ingelheim Talent Acquisition Director
Ms. Lily Chen is heading Talent Acquisition Director in Boehringer Ingelheim, a German based family pharmaceutical company with more than 128 years history and 3,300 employees in China. She joined the company in Oct 2011 when BI started to speed up its expansion in China. Prior to that, Lily has been working with executive search industry for more than 10 years with top notch firms like Korn/Ferry, Amrop Hever focusing on the industrial and real estate practices in Greater China region. She has successfully helped well known MNCs and US/HK listed local companies to place more than hundreds C level candidates. Before starting her career path in the search industry, Lily worked as human resources manager /project manager of a major listed printing group in HK with employees over 3,000 for four years. Lily holds MBA in Finance from Auburn University in US and bachelor of Science degree from Xian University of Engineering, Science & Technology.
|
 |
The Boehringer Ingelheim group is one of the world's 20 leading harmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
Boehringer Ingelheim's business in China is focusing on prescription medicines, consumer healthcare, animal health and international procurement, covering major markets in the country. The company spares no effort in bringing innovative pharmaceutical products to China market, and as a result, Boehringer Ingelheim has obtained a strong recognition for the excellence of its product pipeline covering therapeutic areas ranging from respiratory, cardiovascular to central nerve system medicines. |
|
|
|
SPEAKERS